Currently, ICI are approved for maintenance therapy after a response or stable disease to first-line platinum-based chemotherapy as first-line therapy in cisplatin-ineligible patients with a PD-L1 positive tumor and for platinum-ineligible and refractory patients [3]. The gene discussed is CD274; the disease is neoplasm.